Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141830 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT00141830 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 159 participants.
The verdict
NCT00141830, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).
Interventions
- DRUG Methotrexate plus ERB-041 for 12 weeks
- DRUG Placebo for 12 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141830
The ClinicalTrials.gov registry entry for NCT00141830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate plus ERB-041 for 12 weeks is the first listed.
NCT00141830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141830 about?
NCT00141830 is a clinical study titled "Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis". The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).
What is the current status of trial NCT00141830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2005-08. Estimated completion is 2006-10-19.
What interventions are being tested in trial NCT00141830?
The interventions under investigation include: Methotrexate plus ERB-041 for 12 weeks (DRUG), Placebo for 12 weeks (DRUG).
Who is sponsoring clinical trial NCT00141830?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.